{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:20:22Z","timestamp":1789777222106,"version":"4.0.1"},"reference-count":65,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.clinthera.2024.08.019","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T16:42:23Z","timestamp":1727714543000},"page":"891-899","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["A Randomized Placebo-Controlled Trial of Leronlimab in Mild-To-Moderate COVID-19"],"prefix":"10.1016","volume":"46","author":[{"given":"Harish","family":"Seethamraju","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otto O.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Loftus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onyema","family":"Ogbuagu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Sammartino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonah B.","family":"Sacha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohita","family":"Ojha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott G.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvin Cyrus","family":"Arman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob P.","family":"Lalezari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2024.08.019_bib0001","unstructured":"WHO Coronavirus Disease (COVID-19) Dashboard. Accessed April 15, 2024. https:\/\/data.who.int\/dashboards\/covid19\/cases?n=c."},{"key":"10.1016\/j.clinthera.2024.08.019_bib0002","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2024.08.019_bib0003","article-title":"Effects of environmental factors on severity and mortality of COVID-19","volume":"7","author":"Kifer","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.clinthera.2024.08.019_bib0004","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention","volume":"323","author":"Wu","year":"2020","journal-title":"Jama"},{"key":"10.1016\/j.clinthera.2024.08.019_bib0005","first-page":"12","article-title":"Viral persistence, reactivation, and mechanisms of long COVID","author":"Chen","year":"2023","journal-title":"Elife"},{"key":"10.1016\/j.clinthera.2024.08.019_bib0006","doi-asserted-by":"crossref","first-page":"eadg0033","DOI":"10.1126\/sciimmunol.adg0033","article-title":"Modulation of type I interferon responses potently inhibits SARS-CoV-2 replication and inflammation in rhesus macaques","volume":"8","author":"Viox","year":"2023","journal-title":"Sci Immunol"},{"key":"10.1016\/j.clinthera.2024.08.019_bib0007","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S2213-2600(23)00015-2","article-title":"Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to December, 2022","volume":"11","author":"Wu","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.clinthera.2024.08.019_bib0008","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s11010-021-04325-9","article-title":"Immunomodulatory agents for COVID-19 treatment: possible mechanism of action and immunopathology features","volume":"477","author":"Rommasi","year":"2022","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.clinthera.2024.08.019_bib0009","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S2213-2600(21)00139-9","article-title":"Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context","volume":"9","author":"Angriman","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.clinthera.2024.08.019_bib0010","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1172\/JCI137244","article-title":"Clinical and immunological features of severe and moderate coronavirus disease 2019","volume":"130","author":"Chen","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clinthera.2024.08.019_bib0011","doi-asserted-by":"crossref","first-page":"436","DOI":"10.3390\/vaccines9050436","article-title":"Role of inflammatory cytokines in COVID-19 patients: a review on molecular mechanisms, immune functions, immunopathology and immunomodulatory drugs to counter cytokine storm","volume":"9","author":"Rabaan","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.clinthera.2024.08.019_bib0012","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1080\/22221751.2020.1746199","article-title":"Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia","volume":"9","author":"Lin","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.clinthera.2024.08.019_bib0013","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12985-022-01814-1","article-title":"COVID-19 infection: an overview on cytokine storm and related interventions","volume":"19","author":"Montazersaheb","year":"2022","journal-title":"Virol J"},{"key":"10.1016\/j.clinthera.2024.08.019_bib0014","doi-asserted-by":"crossref","first-page":"e1130","DOI":"10.1093\/cid\/ciaa1759","article-title":"Immunomodulation as treatment for severe Coronavirus Disease 2019: a systematic review of current modalities and future directions","volume":"72","author":"Meyerowitz","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2024.08.019_bib0015","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19 - final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2024.08.019_bib0016","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1056\/NEJMoa2015301","article-title":"Remdesivir for 5 or 10 days in patients with severe Covid-19","volume":"383","author":"Goldman","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2024.08.019_bib0017","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate use of remdesivir for patients with severe Covid-19","volume":"382","author":"Grein","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2024.08.019_bib0018","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2024.08.019_bib0019","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2024.08.019_bib0020","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients","volume":"386","author":"Jayk Bernal","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2024.08.019_bib0021","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2024.08.019_bib0022","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1056\/NEJMoa2019014","article-title":"Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19","volume":"383","author":"Cavalcanti","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2024.08.019_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","volume":"56","author":"Gautret","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.clinthera.2024.08.019_bib0024","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.medmal.2020.03.006","article-title":"No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection","volume":"50","author":"Molina","year":"2020","journal-title":"Med Mal Infect"},{"key":"10.1016\/j.clinthera.2024.08.019_bib0025","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","article-title":"Interleukin-6 receptor antagonists in critically ill patients with Covid-19","volume":"384","author":"Gordon","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2024.08.019_bib0026","doi-asserted-by":"crossref","first-page":"e474","DOI":"10.1016\/S2665-9913(20)30173-9","article-title":"Tocilizumab in patients with severe COVID-19: a retrospective cohort study","volume":"2","author":"Guaraldi","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.clinthera.2024.08.019_bib0027","doi-asserted-by":"crossref","first-page":"6409","DOI":"10.1172\/JCI141772","article-title":"Baricitinib restrains the immune dysregulation in patients with severe COVID-19","volume":"130","author":"Bronte","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clinthera.2024.08.019_bib0028","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa2209760","article-title":"Early treatment with pegylated interferon lambda for Covid-19","volume":"388","author":"Reis","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2024.08.019_bib0029","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa2029849","article-title":"SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19","volume":"384","author":"Chen","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2024.08.019_bib0030","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with Covid-19","volume":"384","author":"Horby","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2024.08.019_bib0031","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/S0140-6736(22)00519-0","article-title":"Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO solidarity randomised trial and updated meta-analyses","volume":"399","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2024.08.019_bib0032","doi-asserted-by":"crossref","first-page":"E242","DOI":"10.1503\/cmaj.211698","article-title":"Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial","volume":"194","author":"Ali","year":"2022","journal-title":"Cmaj"},{"key":"10.1016\/j.clinthera.2024.08.019_bib0033","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(22)00163-5","article-title":"Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"399","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2024.08.019_bib0034","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1111\/hepr.13553","article-title":"Longitudinal changes of liver function and hepatitis B reactivation in COVID-19 patients with pre-existing chronic hepatitis B virus infection","volume":"50","author":"Liu","year":"2020","journal-title":"Hepatol Res"},{"key":"10.1016\/j.clinthera.2024.08.019_bib0035","series-title":"Treating Infectious Diseases in a Microbial World: Report of Two Workshops on Novel Antimicrobial Therapeutics","year":"2006"},{"key":"10.1016\/j.clinthera.2024.08.019_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2021.100083","article-title":"Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: case series of four critically ill patients treated with leronlimab","volume":"4","author":"Agresti","year":"2021","journal-title":"J Transl Autoimmun"},{"key":"10.1016\/j.clinthera.2024.08.019_bib0037","doi-asserted-by":"crossref","first-page":"5602","DOI":"10.4049\/jimmunol.1201018","article-title":"Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth","volume":"189","author":"Schlecker","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.clinthera.2024.08.019_bib0038","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1517\/14728222.2014.949238","article-title":"The potential to target CCL5\/CCR5 in breast cancer","volume":"18","author":"Velasco-Vel\u00e1zquez","year":"2014","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.clinthera.2024.08.019_bib0039","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/exd.13946","article-title":"Expression and biological functions of the CCL5-CCR5 axis in oral lichen planus","volume":"28","author":"Shan","year":"2019","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.clinthera.2024.08.019_bib0040","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.gendis.2021.08.004","article-title":"CCL5\/CCR5 axis in human diseases and related treatments","volume":"9","author":"Zeng","year":"2022","journal-title":"Genes Dis"},{"key":"10.1016\/j.clinthera.2024.08.019_bib0041","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1517\/14728222.2013.837886","article-title":"Targeting CCL5 in inflammation","volume":"17","author":"Marques","year":"2013","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.clinthera.2024.08.019_bib0042","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2478\/raon-2019-0057","article-title":"Cytokine CCL5 and receptor CCR5 axis in glioblastoma multiforme","volume":"53","author":"Kranjc","year":"2019","journal-title":"Radiol Oncol"},{"key":"10.1016\/j.clinthera.2024.08.019_bib0043","doi-asserted-by":"crossref","first-page":"4801","DOI":"10.1158\/0008-5472.CAN-19-1167","article-title":"Recent advances targeting CCR5 for cancer and its role in immuno-oncology","volume":"79","author":"Jiao","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.clinthera.2024.08.019_bib0044","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.3390\/cancers12071765","article-title":"The CCL5\/CCR5 axis in cancer progression","volume":"12","author":"Aldinucci","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clinthera.2024.08.019_bib0045","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.bcp.2008.11.014","article-title":"CCL5 increases lung cancer migration via PI3K, Akt and NF-kappaB pathways","volume":"77","author":"Huang","year":"2009","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.clinthera.2024.08.019_bib0046","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1158\/0008-5472.CAN-17-0915","article-title":"CCR5 governs DNA damage repair and breast cancer stem cell expansion","volume":"78","author":"Jiao","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.clinthera.2024.08.019_bib0047","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1126\/science.1092053","article-title":"Cell migration: integrating signals from front to back","volume":"302","author":"Ridley","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.clinthera.2024.08.019_bib0048","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1096\/fj.201500088R","article-title":"Role of chemokine RANTES in the regulation of perivascular inflammation, T-cell accumulation, and vascular dysfunction in hypertension","volume":"30","author":"Mikolajczyk","year":"2016","journal-title":"Faseb j"},{"key":"10.1016\/j.clinthera.2024.08.019_bib0049","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s10096-020-04138-6","article-title":"COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection","volume":"40","author":"Beyerstedt","year":"2021","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.clinthera.2024.08.019_bib0050","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1128\/JVI.01248-09","article-title":"Differential downregulation of ACE2 by the spike proteins of severe acute respiratory syndrome coronavirus and human coronavirus NL63","volume":"84","author":"Glowacka","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.clinthera.2024.08.019_bib0051","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.700782","article-title":"Immune-based prediction of COVID-19 severity and chronicity decoded using machine learning","volume":"12","author":"Patterson","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.clinthera.2024.08.019_bib0052","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ijid.2020.10.101","article-title":"CCR5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells, and decreases SARS-CoV2 RNA in plasma by day 14","volume":"103","author":"Patterson","year":"2021","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.clinthera.2024.08.019_bib0053","doi-asserted-by":"crossref","first-page":"e4082","DOI":"10.1093\/cid\/ciaa1583","article-title":"Clinical characteristics and outcomes of coronavirus disease 2019 patients who received compassionate-use leronlimab","volume":"73","author":"Yang","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2024.08.019_bib0054","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1056\/NEJMoa2020283","article-title":"Genomewide Association Study of severe Covid-19 with respiratory failure","volume":"383","author":"Ellinghaus","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2024.08.019_bib0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107825","article-title":"Variant-genetic and transcript-expression analysis showed a role for the chemokine-receptor CCR5 in COVID-19 severity","volume":"98","author":"Cuesta-Llavona","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.clinthera.2024.08.019_bib0056","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/15284336.2018.1452842","article-title":"PRO 140, a monoclonal antibody targeting CCR5, as a long-acting, single-agent maintenance therapy for HIV-1 infection","volume":"19","author":"Dhody","year":"2018","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.clinthera.2024.08.019_bib0057","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1128\/AAC.00086-10","article-title":"Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults","volume":"54","author":"Jacobson","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2024.08.019_bib0058","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/COH.0000000000000479","article-title":"The return of PRO 140, a CCR5-directed mAb","volume":"13","author":"Thompson","year":"2018","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.clinthera.2024.08.019_bib0059","doi-asserted-by":"crossref","first-page":"c332","DOI":"10.1136\/bmj.c332","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Schulz","year":"2010","journal-title":"Bmj"},{"key":"10.1016\/j.clinthera.2024.08.019_bib0060","unstructured":"National Early Warning Score (NEWS) 2: standardising the assessment of acute-illness severity in the NHS. Accessed April 15, 2024. https:\/\/www.rcplondon.ac.uk\/projects\/outputs\/national-early-warning-score-news-2."},{"key":"10.1016\/j.clinthera.2024.08.019_bib0061","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1080\/23744235.2020.1784457","article-title":"Predictive value of national early warning score 2 (NEWS2) for intensive care unit admission in patients with SARS-CoV-2 infection","volume":"52","author":"Gidari","year":"2020","journal-title":"Infect Dis (Lond)"},{"key":"10.1016\/j.clinthera.2024.08.019_bib0062","doi-asserted-by":"crossref","first-page":"e234","DOI":"10.3346\/jkms.2020.35.e234","article-title":"Prognostic accuracy of the SIRS, qSOFA, and NEWS for early detection of clinical deterioration in SARS-CoV-2 infected patients","volume":"35","author":"Jang","year":"2020","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.clinthera.2024.08.019_bib0063","doi-asserted-by":"crossref","first-page":"e1004","DOI":"10.1097\/CCM.0000000000004549","article-title":"Evaluation of the risk prediction tools for patients with coronavirus disease 2019 in Wuhan, China: a single-centered, retrospective, observational study","volume":"48","author":"Liu","year":"2020","journal-title":"Crit Care Med"},{"key":"10.1016\/j.clinthera.2024.08.019_bib0064","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13049-020-00764-3","article-title":"National Early Warning Score 2 (NEWS2) on admission predicts severe disease and in-hospital mortality from Covid-19 - a prospective cohort study","volume":"28","author":"Myrstad","year":"2020","journal-title":"Scand J Trauma Resusc Emerg Med"},{"key":"10.1016\/j.clinthera.2024.08.019_bib0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101019","article-title":"Characterizing long COVID in an international cohort: 7 months of symptoms and their impact","volume":"38","author":"Davis","year":"2021","journal-title":"EClinicalMedicine"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824002601?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824002601?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T20:03:17Z","timestamp":1732392197000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291824002601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":65,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0149291824002601"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.08.019","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Randomized Placebo-Controlled Trial of Leronlimab in Mild-To-Moderate COVID-19","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.08.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}